Ulcerative Colitis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Ulcerative Colitis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, Genentech, Inc., Landos Biopharma Inc., Bristol-Myers Squibb, Amgen, Gilead Sciences, Takeda, Sanofi, Celgene, Eli Lilly and Company, Shire.

[Nevada, United States] - DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Ulcerative Colitis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Ulcerative Colitis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Ulcerative Colitis Market Report:
The Ulcerative Colitis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: AbbVie announced a Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
In October, 2024: Bristol-Myers Squibb announces that the purpose of their study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
In October, 2024: Amgen announced that the main purpose of their study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
In October, 2024: Pfizer announced that their study A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled.
In October, 2024: Merck Sharp & Dohme LLC announced that the purpose of their study is to check the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at week 52. Study 2's primary hypothesis.
In September, 2024: Takeda announced a Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
The US accounted for the highest number of diagnosed prevalent ulcerative colitis cases accounting for half of the total cases of 7MM in 2023.
As per the estimates, in 2023 approximately 60% of cases accounted for the moderate to severe cases of ulcerative colitis among the 7MM.
As per survey conducted by Alkhayyat et al., (2020), of the 39,328,760 individuals in the database, 181,670 had Crohn's disease (0.46%) and 154,500 (0.39%) had ulcerative colitis
Key Ulcerative Colitis Companies are as follows: Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, Genentech, Inc., Landos Biopharma Inc., Bristol-Myers Squibb, Amgen, Gilead Sciences, Takeda, Sanofi, Celgene, Eli Lilly and Company, Shire.
Key Ulcerative Colitis Therapies are as follow: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), Lutikizumab, ABBV-668, Guselkumab, Efavaleukin alfa, Etrasimod, Ozanimod, AJM300, ABX464, GS-1427, Ustekinumab, Tulisokibart, Mirikizumab IV
Launching multiple stage Ulcerative Colitis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Ulcerative Colitis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Ulcerative Colitis Overview:
Inflammatory Bowel Disease is an umbrella term used to describe disorders which involve chronic inflammation of the digestive tract. Types of inflammatory bowel disease include Ulcerative Colitis and Crohn's Disease.

Ulcerative Colitis Epidemiology Segmentation:
The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Ulcerative Colitis Age-specific Cases
Ulcerative Colitis Severity-specific Cases
Ulcerative Colitis Total Diagnosed Prevalent Cases
Ulcerative Colitis Total Treated Patients

For more information about Ulcerative Colitis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Ulcerative Colitis Market Insights
In patients with mild-to-moderate ulcerative colitis, current US guidelines recommend first-line treatment with aminosalicylate or sequential induction with corticosteroids followed by aminosalicylate maintenance therapy
In patients with moderate-to-severe ulcerative colitis, an immunosuppressant such as azathioprine or 6-mercaptopurine may be prescribed as maintenance therapy following corticosteroid induction
There have been many advancements in ulcerative colitis treatment over the years. However, safety remains the major challenge in treating ulcerative colitis. There is a lack of a safer, and curative treatment option owing to which the patient's quality of life and daily activities get hampered severely

Ulcerative Colitis Drugs Uptake
Risankizumab is a humanized monoclonal antibody that blocks the binding of IL-23R and activates the pro-inflammatory JAK/STAT intracellular signaling cascade by targeting the p19 component of IL-23.
TREMFYA (guselkumab) is a human monoclonal antibody against the p19 subunit of interleukin (IL)-23 developed by Janssen. IL-23 is an important driver of the pathogenesis of inflammatory diseases such as ulcerative colitis and Crohn's disease
Ozanimod (Zeposia), an S1P receptor modulator, is another recently approved drug for UC. It works by reducing lymphocyte migration to inflamed gut tissues, helping control inflammation.
Several promising therapies are in late-stage clinical trials, such as etrolizumab (an anti-integrin antibody) and upadacitinib (a selective JAK inhibitor). These drugs aim to address the unmet needs of patients who are either refractory or intolerant to current treatments.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Ulcerative Colitis Therapies and Key Companies:
SIMPONI (golimumab): Janssen Pharmaceuticals
ENTYVIO (vedolizumab): Takeda Pharmaceuticals
Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
ABX464 (obefazimod): Abivax
SHR0302 (Ivarmacitinib): Reistone Biopharma
Lutikizumab, ABBV-668: AbbVie
Guselkumab: Janssen Research & Development, LLC
Efavaleukin alfa: Amgen
Etrasimod: Pfizer
Ozanimod: Bristol-Myers Squibb
AJM300: EA Pharma Co., Ltd.
ABX464: Abivax S.A.
GS-1427, Ustekinumab: Gilead Sciences
Tulisokibart: Merck Sharp & Dohme LLC
Mirikizumab IV: Eli Lilly and Company

Ulcerative Colitis Epidemiology:
The Ulcerative Colitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Ulcerative Colitis Market Drivers:
Increasing Prevalence of Ulcerative Colitis
Advancements in Drug Development
Favorable Reimbursement Policies
Growing Awareness and Early Diagnosis

Ulcerative Colitis Market Barriers:
High Treatment Costs
Complex Treatment Algorithms
Competition from Generic Drugs

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Ulcerative Colitis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Ulcerative Colitis Companies: Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, Genentech, Inc., Landos Biopharma Inc., Bristol-Myers Squibb, Amgen, Gilead Sciences, Takeda, Sanofi, Celgene, Eli Lilly and Company, Shire.
Key Ulcerative Colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), Lutikizumab, ABBV-668, Guselkumab, Efavaleukin alfa, Etrasimod, Ozanimod, AJM300, ABX464, GS-1427, Ustekinumab, Tulisokibart, Mirikizumab IV
Ulcerative Colitis Therapeutic Assessment: Current marketed and emerging therapies
Ulcerative Colitis Market Dynamics: Ulcerative Colitis Market drivers and Ulcerative Colitis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Ulcerative Colitis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Ulcerative Colitis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Ulcerative Colitis Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Ulcerative Colitis Executive Summary
6. Ulcerative Colitis Market Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Patient Journey
9. Ulcerative Colitis Marketed Therapies
10. Ulcerative Colitis Emerging Drugs
11. Ulcerative Colitis: The 7MM Analysis
12. Ulcerative Colitis Market Access and Reimbursement
13. Ulcerative Colitis KOL Views
14. Ulcerative Colitis SWOT Analysis
15. Ulcerative Colitis Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.